Fig. 7: Select candidate compounds are able to alleviate the multiple ER stress phenotypes identified in each of the CDG and CDDG lines.
From: Precision genetic cellular models identify therapies protective against ER stress
Following treatment of CDG and CDDG cell lines with optimized concentrations of candidate compounds (6, 9, 15, 26) and a non-active control compound (28), p-eIF2α and ATF6 levels were assessed by immunoblot. A–C Representative images of immunoblots. TNM, tunicamycin (50 nM). (D, E) Quantification of p-eIF2α levels in levels in CDG/CDDG treated cells. (n = 3 per each genotype and treatment). Expression data in (D, E) are relative to expression levels in parental RPE-1 cells. ns, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.001 by one-way ANOVA followed by Dunnett multiple comparisons post-test.
